Avigbagene parvec
AssetAlso FLT201
AAV gene therapy encoding engineered glucocerebrosidase
- Stage
- Phase 3
- Modality
- Gene therapy
- Target
- Autophagy
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Gaucher disease
Phase 3, spurtherapeutics.com, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Evidence for its targets2
- Competitors6
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.